BioCentury
ARTICLE | Clinical News

Serp-1: Phase IIa data

November 23, 2009 8:00 AM UTC

In a double-blind, placebo-controlled Phase IIa trial in 48 patients, IV VT-111 met its primary safety endpoint with no drug-related serious adverse events. VT-111 also significantly reduced levels of...